Introduction
============

Currently, there are no reliable biomarkers for predicting the prognosis of patients who undergo radical cystectomy for bladder cancer. Previous studies have shown that several inflammatory markers, including the neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), lymphocyte-to-platelet ratio (LPR), De Retis and prognostic nutritional index (PNI), are raised as new prognostic factors for number of cancers ([@b1-mco-0-0-02117]).

The NLR, MLR, and LPR represent the ratios of lymphocytes to neutrophils, monocytes, and platelets ([@b4-mco-0-0-02117]). High values of these markers indicate a poor prognosis in the NLR. To the best of our knowledge, no other markers have been reported in bladder cancer ([@b5-mco-0-0-02117]). The detailed mechanisms underlying how these inflammatory cytokines are correlated with cancer progression remain unclear. A candidate mechanism involves malignant disease enhancing inflammation, thereby affecting regulatory T cells ([@b4-mco-0-0-02117],[@b6-mco-0-0-02117]). Cancer progression decreases the number of lymphocytes, which increases the NLR and MLR and decreases the LPR ([@b4-mco-0-0-02117],[@b6-mco-0-0-02117]).

Studies have shown that the PNI was correlated with the prognosis in several malignancies including lung and gastrointestinal cancers ([@b2-mco-0-0-02117],[@b7-mco-0-0-02117]). Systemic inflammation increased tumorigenesis and cancer progression, resulting in low albumin levels and immunosuppression ([@b3-mco-0-0-02117]). This phenomenon has been reported in colon, gastric, lung, and pancreatic cancers ([@b8-mco-0-0-02117]).

De Ritis is calculated as the aspartate transaminase (AST) levels divided by alanine transaminase (ALT) levels, as first reported by Fernando De Ritis in 1957([@b8-mco-0-0-02117]). This marker does not evaluate liver function but rather indicates the severity of liver dysfunction ([@b8-mco-0-0-02117]). In genitourinary cancer, a high De Ritis ratio was reported to be a poor prognostic marker in prostate, renal, and urothelial carcinoma. In other solid malignancies including breast and lung cancer, a high De Ritis ratio was also reported to be a poor prognostic marker ([@b8-mco-0-0-02117]).

The present study aimed to assess the most reliable inflammatory tumor marker in bladder cancer patients who have undergone radical cystectomy.

Patients and methods
====================

A total of 161 cases underwent radical cystectomy between April 1994 and April 2014 at Yokohama City University Medical Center (Yokohama, Japan). The median and mean follow-up periods were 29.2 and 39.4±31.4 months and all patients were \>18 years. Of these patients, the 107 who had data for the NLR, MLR, LPR, De Ritis and PNI were enrolled in the present study ([Table I](#tI-mco-0-0-02117){ref-type="table"}). The PNI is calculated using the albumin and lymphocyte count with the following formula: PNI=(10 x albumin) + (0.005 x total lymphocyte count) ([@b7-mco-0-0-02117]). A total of 31 (29.2%) cases received cisplatin-based neo-adjuvant systemic chemotherapy. Laboratory data, including complete blood cell count (CBCs) and albumin, AST and ALT levels, were obtained a few days before surgery. CBCs included the number of blood cells, platelets and white blood cells with differentiation. None of the patients showed systemic inflammation or blood disease at the time of the blood test. The criteria of systemic inflammation were determined as fever and elevation of serum C-reactive protein (CRP) levels. In the present cohort, none of the patients had fever and CRP elevation. The median value was used as the cut-off value of each factor as follows: NLR, 1.00; MLR, 0.24: LPR, 73.9; PNI, 44.0 and De Ritis, 1.1. Receiver operator characteristic (ROC) curves were plotted to show candidate cutoff points. The candidate cutoff points and the area under the ROC (AUROC) are shown in [Table II](#tII-mco-0-0-02117){ref-type="table"}. Postoperative complications were assessed using the Clavien-Dindo Grading System and the existence of surgical complications was defined by the presence of complications classified as Clavien-Dindo Grade I or higher ([@b9-mco-0-0-02117]). The Institutional Review Board of Yokohama City University Medical Center (Yokohama, Japan) approved the present study (approval no. D1507018) and written informed consent was waivered due to the nature of the retrospective observational study without patient identification.

The preoperative NLR, MLR LPR, De Ritis and PNI were examined as prognostic factors for recurrence-free survival (RFS) and overall survival (OS). A Kaplan-Meier product limit estimate was used to estimate the OS and RFS. The log-rank test was performed to compare each risk factor. Values between neoadjyuvant chemotherapy (NAC) and non-NAC groups were compared. P\<0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed using the GraphPad Prism 7.0 (GraphPad Software, Inc.).

Results
=======

Regarding the RFS, the only noteworthy finding was that a lower PNI was associated with a significantly lower RFS compared with higher PNI (P=0.028). Regarding the OS, lower LPR and PNI were associated with significantly lower OS compared with higher values (more than median value) (P=0.048 and P=0.036, respectively). When the cutoff point was set as the median value, the other inflammatory markers showed no significant association with either the RFS or OS ([Fig. 1](#f1-mco-0-0-02117){ref-type="fig"}). When the cutoff point was set using the ROC curve, a lower PNI was associated with significantly lower RFS and OS (P=0.0143 and P=0.0216, respectively; [Fig. 2](#f2-mco-0-0-02117){ref-type="fig"}). Based on these findings, De Ritis was evaluated as a prognostic risk factor after radical cystectomy. No differences were observed between these systemic inflammatory markers and the pT stage, lymph node metastasis, age, neo-adjuvant systemic chemotherapy or sex ([Table SI](#SD1-mco-0-0-02117){ref-type="supplementary-material"}).

Discussion
==========

The current strategy for the treatment muscle-invasive bladder cancer is based on staging using imaging modalities ([@b3-mco-0-0-02117]). For non-metastatic muscle-invasive bladder cancer, radical cystectomy is the gold standard treatment ([@b3-mco-0-0-02117]). While radical cystectomy has proven effective, the recurrence rate is still not entirely sufficient ([@b4-mco-0-0-02117]). Thus, preoperative risk management is necessary. Previous studies have revealed the usefulness of inflammatory markers in several solid malignancies, including bladder cancer ([@b2-mco-0-0-02117]).

The present study examined the effectiveness of systemic inflammatory markers, including NLR, PNI, MLR, and LPR for predicting prognosis of bladder cancer. In addition, the utility of De Ritis was evaluated as a prognostic risk factor after radical cystectomy. A lower PNI was found to be associated with a significantly poorer prognosis in both the RFS and OS. This suggested that albumin may play a role in bladder cancer progression, in addition to lymphocytes. Therefore, a lower preoperative PNI predicted an increased risk of recurrence, which suggested that several adjuvant or neo-adjuvant therapies should be performed in combination with radical cystectomy.

Onodera *et al* revealed that a PNI of \>45 denoted a low risk of surgical complications, a PNI of 40-45 denoted a high risk of surgical complications and a PNI of \<40 suggested that surgery should be avoided ([@b10-mco-0-0-02117]). A recent study showed that the PNI was correlated with the prognosis of several malignancies including lymphoma and pancreas cancer ([@b11-mco-0-0-02117],[@b12-mco-0-0-02117]). Systemic inflammation increases tumorigenesis and cancer progression, resulting in low albumin levels and immunosuppression ([@b7-mco-0-0-02117]). This phenomenon has been reported in colon, gastric, lung, and pancreatic cancers ([@b7-mco-0-0-02117]). Although nutrition plays an important role in patients undergoing radical cystectomy, no studies have reported a correlation between the PNI and survival and recurrence ([@b13-mco-0-0-02117]).

Several limitations associated with the present study warrant mention. First, the present study initially used median values and values determined based on ROC curves as candidate cutoff points. Until now, no established cut-off point has been determined. Although median value might have included some good cutoff points, the median value cutoff points determined from ROC curves were ultimately used for analysis. The PNI demonstrated significance using both sets of cutoff points. Second, the number of patients was relatively small. Therefore, further studies are needed in order to validate the superiority of the PNI to other markers. Third, patients from 1994 to 2014 were included. Although there have been improvements in muscle invasive bladder cancer treatment such as development of gemcitabine and cisplatin treatment, there have been no dramatic changes until 2018. Until 2018, immune-checkpoint inhibitors were not permitted for daily clinical use. Furthermore, none of the patients in the present cohort received pembrolizumab.

In conclusion, the present study revealed that a low PNI more accurately predicted lower RFS and OS compared with other systemic inflammatory risk factors.
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###### Marker values in non-NAC and NAC groups.

Not applicable.
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###### 

Patient characteristics.

  Characteristics                    No. of subjects (%)
  ---------------------------------- ---------------------
  Age, years                          
       \<65                          42 (39.3)
       ≥65                           65 (60.7)
  Prognosis                           
       Alive                         79 (73.8)
       Death                         28 (26.2)
  Neo-adjuvant chemotherapy           
       Yes                           31 (29.2)
       No                            76 (71.0)
       Recurrence                    33 (30.8)
  Pathological T stage                
       ≤2                            53 (49.5)
       ≥3                            54 (50.5)
  Pathological N stage                
       Positive                      17 (15.9)
       Postoperative complications   21 (19.6)

n=107.

###### 

Candidate cutoff points determined using ROC analyses.

  A, Overall survival                    
  ----------------------------- -------- --------------
  NLR                           0.6044   2.38
  MLR                           0.5136   0.18
  LPR                           0.5927   71.60
  PNI                           0.6731   47.90
  De Ritis                      0.6022   1.30
  B, Recurrence free survival            
  Marker                        AUROC    Cutoff value
  NLR                           0.5123   2.38
  MLR                           0.5381   0.25
  LPR                           0.5135   71.60
  PNI                           0.6605   47.90
  De Ritis                      0.5561   1.08

ROC, receiver operating characteristic; AUROC, area under the ROC; NLR, neutrophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; LPR, lymphocyte-to-platelet ratio; PNI, prognostic nutritional index.
